Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.40 |
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28015994 | 0.80 | ACHE (0.34) | BCHEACHEHTR6 | |
| SCHEMBL28003598 | 0.79 | HTR6 (0.50) | PTPN1CNR1BCHEACHEHTR6 | |
| SCHEMBL6055979 | 0.79 | PTPN1 (0.49) | PTPN1CYSLTR2CYSLTR1CNR1BCHE | |
| SCHEMBL2463719 | 0.78 | MAPT (0.50) | — | |
| SCHEMBL17417245 | 0.78 | MAPT (0.50) | — | |
| SCHEMBL6866716 | 0.78 | MAPT (0.50) | — | |
| Acetic Acid SCHEMBL9526438 | 0.78 | RXFP1 (0.46) | — | |
| SCHEMBL8158524 | 0.78 | PTPN1 (0.41) | PTPN1CYSLTR2CYSLTR1CNR1BCHE | |
| SCHEMBL27711027 | 0.76 | PTPN1 (0.40) | PTPN1CYSLTR2CYSLTR1CNR1BCHE | |
| SCHEMBL8160512 | 0.75 | CNR1 (0.40) | PTPN1CYSLTR2CYSLTR1CNR1BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10583140-B2 | Ingenol analogs, pharmaceutical compositions and methods of use thereof | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-03-10 | — | — | US | disclosed |
| US-20190030029-A1 | INGENOL ANALOGS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-01-31 | — | — | US | disclosed |
| EP-2655323-B1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | LEO LABORATORIES LTD (IE) | 2017-12-20 | — | — | EP | disclosed |
| US-20170217910-A1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | LEO LABORATORIES LIMITED (IE) | 2017-08-03 | — | — | US | disclosed |
| WO-2017130156-A1 | INGENOL ANALOGS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-08-03 | — | — | WO | disclosed |
| US-9708286-B2 | Ingenol-3-acylates III and ingenol-3-carbamates | LEO LABORATORIES LIMITED (IE) | 2017-07-18 | — | — | US | disclosed |
| US-9656945-B2 | 3-acyl-ingenols II | LEO LABORATORIES LIMITED (IE) | 2017-05-23 | — | — | US | disclosed |
| US-9409931-B1 | 3-O-acyl-ingenol analogues | LEO LABORATORIES LIMITED (IE) | 2016-08-09 | — | — | US | disclosed |
| US-9409931-B1 | 3-O-acyl-ingenol analogues | LEO LABORATORIES LIMITED (IE) | 2016-08-09 | — | — | US | disclosed |
| US-9388124-B2 | Ingenol-3-acylates I | LEO LABORATORIES LIMITED (IE) | 2016-07-12 | — | — | US | disclosed |
| US-9102687-B2 | Ingenol-3-acylates III and ingenol-3-carbamates | LEO LABORATORIES LIMITED (IE) | 2015-08-11 | — | — | US | disclosed |
| US-20140303150-A1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | LEO LABORATORIES LIMITED (IE) | 2014-10-09 | — | — | US | disclosed |
| US-20130331446-A1 | 3-ACYL-INGENOLS II | LEO LABORATORIES LIMITED (IE) | 2013-12-12 | — | — | US | disclosed |
| US-20130324600-A1 | INGENOL-3-ACYLATES I | LEO LABORATORIES LIMITED (IE) | 2013-12-05 | — | — | US | disclosed |
| EP-2655312-A1 | 3-ACYL-INGENOLS II | LEO LABORATORIES LIMITED (IE) | 2013-10-30 | — | — | EP | disclosed |
| EP-2655323-A1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | LEO LABORATORIES LIMITED (IE) | 2013-10-30 | — | — | EP | disclosed |
| EP-2655311-A1 | INGENOL-3-ACYLATES I | LEO LABORATORIES LIMITED (IE) | 2013-10-30 | — | — | EP | disclosed |
| WO-2012085189-A1 | INGENOL-3-ACYLATES I | LEO PHARMA A/S (DK) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012083954-A1 | 3-ACYL-INGENOLS II | LEO PHARMA A/S (DK) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012083953-A1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | LEO PHARMA A/S (DK) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130324600-A1 | INGENOL-3-ACYLATES I | CXCL8, MMP8, CASP8 | PTPN1 4199/4885CYSLTR2 178/4885CYSLTR1 120/4885 |
| US-20170217910-A1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | RXRB, RXRA, RXRG | PTPN1 3641/4885CYSLTR2 193/4885CYSLTR1 102/4885 |
| US-20130331446-A1 | 3-ACYL-INGENOLS II | IL33, CXCL8, MMP8 | PTPN1 4485/4885CYSLTR2 47/4885CYSLTR1 55/4885 |
| US-20190030029-A1 | INGENOL ANALOGS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | ERG28, PTH1R, CCR5 | PTPN1 3530/4885CYSLTR2 144/4885CYSLTR1 187/4885 |
| US-20140303150-A1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | RXRB, RXRA, RXRG | PTPN1 3641/4885CYSLTR2 193/4885CYSLTR1 102/4885 |
| US-10583140-B2 | Ingenol analogs, pharmaceutical compositions and methods of use thereof | ERG28, PTH1R, CCR5 | PTPN1 3530/4885CYSLTR2 144/4885CYSLTR1 187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.